Newsletter sign up


ADC University Our services

ADC Review
is made possible by:



Copyright 2017
Terms & Conditions


PEER-REVIEWED ARTICLES

Americas Antibody Congress 2017

FRESH DATA. EXPERT SPEAKERS. DEEP CONTENT.

This May, researchers from pharma, academia, and biotech will descend on San Diego for two days of networking and content on the challenges to the antibody industry presented by the increased demand for antibody drugs to fight chronic illnesses.

With demand comes innovation. The only antibody event with new data and non-repetitive talks as a requirement to speak, Americas Antibody Congress 2017 will feature sessions on New Data in Antibody Discovery, New Data in Clinical and Commercial Development, and the therapeutic areas of Infectious Diseases and Oncology.

Download the brochure

Click here tot register


 

World Immunotherapy Congress USA 2017

Discover. Develop. Get to market. For Biotech, Pharma, and Their Partners.

The demand for innovation in immunotherapy can only grow, and new breakthroughs are needed if success rates are to continue. That’s why World Immunotherapy Congress is coming to the USA after an acclaimed launch in Europe. This inaugural event will bring together the brightest and best minds in pharma, biotech, government and academia to build on the development and commercialization of new immunotherapy treatments.

Co-located with the Americas Antibody Congress, Immunotherapy World Congress USA features 2 days of in-depth case studies and discussions around Cell Therapy Strategies, Pre-Clinical Development and Innovative Therapeutic Approaches presented by our partners from biopharma and academia.

Click here to register.


 

CPhI | Pre-Connect Congress 2017

CPhI’s Pre-Connect Congress is the ‘Pharma Leaders’ Destination’ – a one day Congress taking place the day before the CPhI Worldwide Exhibition and covering the latest trends and developments in Pharma across a variety of sectors.

The Pre-Connect Congress is the only event to cover the full spectrum of the Pharma value chain.

Join us in Frankfurt on 23rd October for a series of thought provoking presentations, interactive panel discussions and dedicated networking opportunities, helping you to do better business in Pharma.

CPhI North America


Coming to Philadelphia, PA, USA May 16-18, 2017 is the only event which offers you access to the complete North American pharmaceutical supply chain – CPhI North America – alongside the leading fine & specialty chemical event – InformEx. Source your business solutions with 450+ suppliers, network with 6,000+ industry players, and stay ahead of industry trends with the first-ever Connect Conference featuring 8 tracks or at one of the show floor presentations – all under one roof! To learn more, go to cphinorthamerica.com or informex.com today!

CPhI North America
CPhI North America is the only event in North America to offer you access to the complete pharma supply chain. From fine chemicals to pharma ingredients to finished formulations to packaging – all of your business solutions are under one roof! Taking place in Philadelphia, PA, USA May 16-18, 2017 this is your opportunity to source products and services from 450+ suppliers, network with 6,000+ industry players, and stay ahead of industry trends with the first-ever CPhI Connect Conference featuring 40+ hours of cutting-edge content or at one of the show floor presentations – all under one roof! To learn more, go to cphinorthamerica.com today!

InformEx
InformEx, the leading fine & specialty chemical event in North America for 32+ years, is taking place in Philadelphia, PA, USA May 16-18, 2017. This is your opportunity to source products and services from 150+ suppliers, network with 6,000+ specialty chemical and pharma industry players, and stay ahead of industry trends with the first-ever InformEx Connect Conference featuring 40+ hours of cutting-edge content or at one of the show floor presentations – all under one roof! To learn more, go to informex.com today!

Click here to attend.



7th Annual World ADC Berlin 2017

The last 12 months has seen a staggering amount of progress in ADCs.

There are now 50+ compounds in the clinic; with approval of Pfizer’s Inotuzumab Ozogamicin expected later this year. Coupled with this, there is a bulging preclinical pipeline of 92 ADCs and counting.

In 2017, 300+ of the leading ADC minds will descend on the 7th Annual World ADC Berlin meeting (20-22 February) to share experiences, data and insights on how to develop the next generation of clinically impactful ADCs. Across three streams, every element of ADC development is addressed providing you with an unrivalled forum for learning.

The 2017 World ADC Berlin program has been designed to reflect these progressive innovations developing next-generation ADCs.

The meeting will be held in the Maritim proArte Hotel Berlin,  Friedrichstraße 151,  Berlin,  10117, Germany

Antibody–Drug Conjugates: Oncology and Beyond

Antibody–Drug Conjugates (ADCs) combine the selectivity of antibodies with the efficacy of small molecule drugs, allowing for more precise therapeutic approaches. This symposium will explore the opportunities and challenges of ADCs for cancer, and the need to resolve these open questions in order to fulfill the larger promise of this technology. We will also consider use of ADCs beyond cancer into other disease indications including autoimmune disease, difficult-to-treat bacterial infections, and atherosclerosis.


Organizers  Speakers
Gene Dubowchik, Ph.D,
Bristol-Myers Squibb
Philip E. Brandish, Ph.D,
Merck & Co.
Lynn M. Abell, Ph.D,
Bristol-Myers Squibb
Ryan Fleming, Ph.D,
MedImmune
Pamela A. Trail, Ph.D,
Regeneron Pharmaceuticals Inc.
Rakesh K. Jain, Ph.D,
Harvard University
Sonya Dougal, Ph.D,
The New York Academy of Sciences
Christopher J. O’Donnell, Ph.D,
Pfizer
Caitlin McOmish, Ph.D,
The New York Academy of Sciences
Laura Saunders, Ph.D,
AbbVie
Greg Thurber, Ph.D
University of Michigan

Note: Poster Abstract Deadline is September 15, 2017

Photo: New York city skyline. Courtesy: © 2017 Fotolia. Used with permission.

Exploring ADC Pharmacokinetics using QSP Modeling Strategies

A webinar presented by Joshua Apgar, Ph.D, Co-Founder and CSO of Applied BioMath, will show how quantitative systems pharmacology (QSP) modeling approaches provided biological insights into the impact of drug-to-antibody (DAR) ratio and the resulting changes in molecular properties on overall pharmacokinetics (PK) and relative payload disposition as observed in preclinical studies.

“We used QSP modeling to explore the PK of antibody-drug conjugate (ADC) therapeutics which typically show a discrepancy between the PK of total antibody and that of conjugated antibody, carrying one or more payload molecules,” Apgar said.

“This discrepancy is often attributed to deconjugation, however recent evidence suggests that the underlying mechanisms may be more complex. Modeling helps generate hypotheses that predict this complex behavior,” he noted.

“This ADC case study is a great example of how Model-Aided Drug Invention (MADI) helps project teams quickly discern important characteristics of a platform or drug candidate,” explained John Burke, Ph.D, Co-Founder, President, and CEO of Applied BioMath.

“We often hear from our clients how valuable these biological and drug insights, sometimes counterintuitive, are as it helps accelerate drug candidates into the clinic and to then better ensure the likelihood of testing proof of clinical concept,” Burke added

This webinar will air live at 2pm ET / 11am PT and is ideal for scientists interested in how computational models can be used to design novel ADCs and to optimize the discovery and development of existing ADCs.

2nd Annual Cancer Immunotherapy Summit

Vonlanthen Group of Companies, a fast-growing multinational company that is an experienced provider of conferences, summits, exhibitions, and training programs, producing events within 6 different industries,will be hosting the 2nd Annual Cancer Immunotherapy Summit on September 21st – 22nd, 2017 in Vienna, Austria.

Following the success of the 1st Annual Cancer Immunotherapy Summit and the continued viability of immunotherapy as a cancer treatment we bring the second instalment in the series.

Immunotherapy upholds as being one of the most successful approaches to cancer treatment since the discovery of chemotherapy. To pursue this option as a feasible form of treatment, there needs to be an adequate forum for experts to share their findings and technologies. The purpose of this Summit is to bring experts, scientists, and researchers together to discuss the latest research, advancements, and developments in immunotherapy to continue the successful development of this as a form of cancer treatment.

Dr. Saso Cemerski, Principal Scientist, Merck Sharp & Dohme Ltd, USA and chairman of the event, states the importance of this topic and the need for this event: ‘Cancer treatment has moved into a new era with therapies that target the immune system showing unprecedented success in previously difficult to treat indications. While targeting negative T-cell regulators, PD-1 and CTLA-4, drove much of the initial success it also created an immediate need to identify new targets on T-cells and other immune cells present in the tumour microenvironment. Next generation targets, next generation combinations, new technologies and platforms are all critical factors that will allow improvement of the initial clinical success immuno-oncology as a field has brought to patients.

As we continue to work bringing forward from discovery into clinical development drugs that demonstrate strong preclinical proof of concept, we also continue to learn through reverse translation how to best define patient population that will respond to new therapies, how to design best biomarker plans and ultimately, design the best protocols for clinical trials. The 2nd Annual Cancer Immunotherapy Summit will surely be a great opportunity to share some of the latest research and development in the field and stimulate additional progress in the future.’

We are assembling innovators from oncology, drug development, antibody engineering, cell and gene therapy, and others for a two-day summit to espouse the latest developments in Cancer Immunotherapy research. Through a detailed outlay of the current state and future progressions in this form of treatment, attendees will be exposed to new findings. This will include:

  • The success of antibodies in therapeutics and engineering
  • The potential of the next generation immune checkpoint pathways
  • Revolutionary cancer treatments with personalized cancer vaccines
  • Reinforcing anti-tumour immunity
  • Managing unique immune-mediated adverse reactions and toxicity effects in treatment therapies
  • Progressions in genetic engineering techniques and progressions in preclinical and clinical Cancer Immunotherapy
  • Car T-cell therapy as an influence on cancer treatment
  • Regulatory aspects of the EU and the rest of the world for immunotherapy

We are excited to be hosting this critical event, as the outcome will have a lasting impact on cancer treatment therapies. Join us for what will be an engaging and insightful opportunity for those concerned with Cancer Immunotherapy development. Registration is available till September 19, 2017.


 

8th World ADC – San Diego

Now in it’s 8th year, World ADC in San Diego , CA, shares novel science with transformative research to power the development of more therapeutically effective Antibody-drug Conjugates (ADCs).

This multi-stream, 4 day event covers every element of ADCs from early discovery to marketization. Distilling new insights and data with lessons learned, attendees will be able to craft their own ADC conference focused on your specific challenges.

As the industry’s definitive conference, this antibody drug conjugate conference provides you with an unrivaled forum for learning to propel your ADC program forward tomorrow.

Organized by Hanson Wade, the 8th World ADC in San Diego will be held at Sheraton San Diego Marina, 1380 Harbor Island Dr, San Diego, CA 92101, United States.


Special Discount
Plan to Attend the 8th Annual World ADC Summit in September! As a subscriber get 10% discount when you quote promotional code ADCR10.


 

Antibody Drug Conjugates Summit

The Vonlanthen Group is pleased to invite you to the Antibody Drug Conjugates Summit scheduled to take place on February 25-26, 2016 in Vienna, Austria.

This innovative B2B event will enable the participants to learn about protein modeling development and engineering advances, preclinical and clinical improvements, current ADC linker chemistry- better linker design for future generations, improving preclinical and clinical translation and creating strong and scalable processes.

Key Practical Learning Points of the Summit:

  • Increase benefits of ADC- dial in potency, target stratified patient populations and optimize dosing regimens
  • Ensure product and process robustness
  • Make more evidence-based decisions
  • Explore alternative opportunities for ADCs by reviewing the potential of using ADCs outside oncology
  • Learn about advances in Protein Modeling and Engineering Breakthroughs
  • How to screen for optimal site of conjugation, select better quality targets and explore new payload mechanisms of action?
  • Linker Design Decisions, Novel Payloads and Linker Technology, Next-Generation Chemistry for Improved Conjugation and Linker Stability
  • Characterization of ADCs, Preclinical and Clinical Advances, Translational Considerations
  • Engineering ADCs for Developability, Enhanced Specificity and Binding, and Reduced Toxicity

Who Should Attend:
CEOs, Directors, Heads & Managers Of Leading Application Creators & Suppliers Including:

  • Toxicology
  • Biologics
  • Molecular Biology
  • Chief Technology Officer; Chief Development Officer; Chief Scientific Officer; Senior Research Officer
  • Biotherapeutics; Molecular Medicine; Data analysis; Analytical & Formulation
  • Oncology Drug Development; Oncology Molecules
  • Medical information
  • Bioanalytical
  • Discovery Chemistry; Research & Development; Antibody Discovery
  • Protein Engineering; Process Sciences
  • Biopharmaceutical Development; Development Analytics and New Technologies:
  • Clinical Assay; Biologics Discovery and Design

It is also designed for professionals who work for the Industry of:

  • Pharmaceuticals,
  • Biologics,
  • Medicine;
  • Clinical Research Organizations;
  • Academic Research Centers;
  • Regulatory Agencies

 


Skip to toolbar